Analytical characterisation of an AAV9 gene therapy

被引：0
|
作者：
Perez, S. [1 ]
Bagnati, M. [1 ]
Gamlen, T. [2 ]
Yang, Z. L. [2 ]
Marginean, D. [1 ]
Rossi, F. [1 ]
Thompson, S. [1 ]
O'Grady, C. [1 ]
Li, L. [1 ]
Hautbergue, G. M. [3 ]
Azzouz, M. [2 ,3 ]
Barreira, M. [1 ]
机构：
[1] Cell & Gene Therapy Catapult, London, England
[2] Univ Sheffield, Gene Therapy Mfg & Innovat Ctr GTIMC, Sheffield, S Yorkshire, England
[3] Univ Sheffield, Sheffield Inst Translat Neurosci SITraN, Dept Neurosci, Sheffield, S Yorkshire, England
来源：
HUMAN GENE THERAPY | 2024年 / 35卷 / 3-4期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P112
引用
收藏
页码：A85 / A85
页数：1
相关论文
共 50 条
  • [41] Intracisternal administration of AAV9 gene therapies to target the central nervous system
    Pukenas, Bryan
    Papisov, Mikhail
    Buss, Nicholas
    Karumuthil-Melethil, Subha
    O'Berry, Anthony
    Cowley, Kirsten
    Nevoret, Marie-Laure
    Falabella, Paulo
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S89 - S89
  • [42] Directed Evolution of AAV9 for Efficient Gene Expression in Cardiomyocytes In Vitro and In Vivo
    Huettermann, Leonard
    Schroeder, Lena C.
    Shetty, Prithviraj M. V.
    Jonker, Timo
    Hille, Susanne S.
    Kliesow Remes, Anca
    Matzen, Andrea
    Grimm, Dirk
    Frank, Derk
    Boink, Gerard J. J.
    Eschenhagen, Thomas
    Schade, Dennis
    Mueller, Oliver J.
    HUMAN GENE THERAPY, 2025,
  • [43] The advent of AAV9 expands applications for brain and spinal cord gene delivery
    Dayton, Robert D.
    Wang, David B.
    Klein, Ronald L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (06) : 757 - 766
  • [44] Characterization of HSV Derived AAV9 Vectors
    Pechan, Peter
    Golebiowski, Diane
    Seregin, Alexey
    Zapata, Nicole
    Levi, Elise
    Kitsos, Christine
    Lu, Robert
    Amorrortu, Alvaro
    Morris, Carl
    MOLECULAR THERAPY, 2019, 27 (04) : 347 - 347
  • [45] Identification and validation of target receptors for AAV9
    Roach, M.
    Webster, C.
    Azzouz, M.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A56 - A56
  • [46] Regenxbio gets $40 million for AAV9
    Cross, Ryan
    CHEMICAL & ENGINEERING NEWS, 2018, 96 (45) : 15 - 15
  • [47] Deamidation Drives AAV9 Potency Loss
    Smith, Austin E.
    Murphy, Michael
    Ollosi, Stephen
    MOLECULAR THERAPY, 2024, 32 (04) : 442 - 442
  • [48] Identification and Validation of Target Receptors for AAV9
    Roach, Matthew
    Azzouz, Mimoun
    Webster, Christopher
    MOLECULAR THERAPY, 2022, 30 (04) : 426 - 426
  • [49] Transcytosis of AAV8 and AAV9 across Endothelial Barrier
    He, Bo
    Yuan, Zhenhua
    Qiao, Chunping
    Madden, Victoria
    Thakker, Dhiren
    Li, Juan
    Xiao, Xiao
    MOLECULAR THERAPY, 2009, 17 : S175 - S175
  • [50] Gene therapy strategy for Amyotrophic Lateral Sclerosis using recombinant AAV9 vectors to silence the mutant SOD1 gene
    Biferi, Maria Grazia
    Cohen-Tannoudji, Mathilde
    Rode, Marianne
    Barkats, Martine
    HUMAN GENE THERAPY, 2012, 23 (10) : A127 - A127
12345